Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), today […]
INCHEON, South Korea–(BUSINESS WIRE)–Celltrion, Inc. (KRX:068270) signed an ‘Incubation’ agreement with Emory University in Atlanta to support the research and development of new drug candidates for ath […]
Source: https://www.linkedin.com/pulse/evaluation-clinical-trial-costs-barriers-drug-luca-dezzani-md/
The complete analysis of the costs and barriers to drug development in 2018. All the expenses to conduct […]
PFÄFFIKON, Switzerland–(BUSINESS WIRE)–Numab Therapeutics AG, a biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer, today announced it appointed Dr. […]
HOUSTON & LONDON–(BUSINESS WIRE)–Cell Medica announces the treatment of the first patient world-wide to receive CMD-501, an autologous CAR-NKT therapy targeting pediatric neuroblastoma. This is the first time an […]
Latest Activity See All Items
Lucy Muniz wrote a new post, CAR-T Pioneer Dr. Stephan A. Grupp to Join Cellectis Clinical Advisory Board 5 hours, 53 minutes ago
NEW YORK–(BUSINESS WIRE)–Regulatory News:
Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), today […]
Lucy Muniz wrote a new post, Celltrion Signs ‘Incubation’ Agreement with Emory University for Development of New Drugs for Atherosclerosis 5 hours, 54 minutes ago
INCHEON, South Korea–(BUSINESS WIRE)–Celltrion, Inc. (KRX:068270) signed an ‘Incubation’ agreement with Emory University in Atlanta to support the research and development of new drug candidates for ath […]
Lucy Muniz wrote a new post, Evaluation of Clinical Trial Costs and Barriers to Drug Development By Luca Dezzani Group Global Medical Director at Novartis Oncology 7 hours, 58 minutes ago
Source: https://www.linkedin.com/pulse/evaluation-clinical-trial-costs-barriers-drug-luca-dezzani-md/
The complete analysis of the costs and barriers to drug development in 2018. All the expenses to conduct […]
Lucy Muniz wrote a new post, Numab Appoints Immunotherapy Pioneer Ignacio Melero as Scientific Advisor 8 hours, 44 minutes ago
PFÄFFIKON, Switzerland–(BUSINESS WIRE)–Numab Therapeutics AG, a biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer, today announced it appointed Dr. […]
Lucy Muniz wrote a new post, Cell Medica: First Neuroblastoma Patient Successfully Dosed with Innovative CAR Therapy Utilizing Natural Killer T Cells (CAR-NKT) 8 hours, 44 minutes ago
HOUSTON & LONDON–(BUSINESS WIRE)–Cell Medica announces the treatment of the first patient world-wide to receive CMD-501, an autologous CAR-NKT therapy targeting pediatric neuroblastoma. This is the first time an […]